Veozah vs Intrarosa: Long-Term Durability of Response Compared

What These Two Drugs Actually Do (and Why Comparing Them Is Complicated)

Veozah and Intrarosa work in entirely different parts of your body, for different menopause symptoms. Comparing their "durability" is a bit like comparing how long a blood-pressure pill controls hypertension versus how long a topical antifungal clears an infection. The question is real, but the answer depends on which symptom you are treating.

Fezolinetant (Veozah) is a neurokinin 3 receptor (NK3R) antagonist. It blocks the signaling pathway in the hypothalamus that drives hot flashes and night sweats. It has FDA approval for moderate-to-severe vasomotor symptoms (VMS) in menopause and contains no hormones.

Prasterone (Intrarosa) is a vaginal insert containing DHEA, a precursor hormone that vaginal cells convert locally into estrogen and testosterone. It holds FDA approval specifically for dyspareunia (painful intercourse) due to GSM. It works locally, not centrally.

Many postmenopausal women have both VMS and GSM. In that situation, these two drugs may complement rather than replace each other. The switching question, "should I drop one for the other," usually only makes sense if you are trying to simplify a regimen or if one is not performing as expected.

The Symptom Mismatch Problem

If you are still waking three times a night drenched in sweat, Intrarosa will not fix that. If penetration remains painful despite fewer hot flashes, Veozah will not fix that either. Matching drug to symptom is the starting point for any durability comparison.

Where the Evidence Gaps Are

Women were historically underrepresented in cardiovascular and neuroscience trials, but both fezolinetant and prasterone were studied primarily in postmenopausal women. The sex-specific data here is actually stronger than in many drug classes. Still, long-term head-to-head durability data beyond 52 weeks for Veozah and beyond 12 weeks for Intrarosa (in key trials) does not yet exist. Real-world registry data for Intrarosa extends longer, but that evidence is observational.

Veozah (Fezolinetant): How Long Does It Keep Working?

Fezolinetant's durability through 52 weeks is the most clinically meaningful number currently available, and the data are encouraging.

SKYLIGHT-1: The 52-Week Landmark

The SKYLIGHT-1 trial (Lancet, 2023) was a randomized, double-blind, placebo-controlled study in 599 postmenopausal women with at least seven moderate-to-severe hot flashes per day. The 45 mg once-daily dose reduced mean daily VMS frequency by 60.3% from baseline at week 12, and that reduction was sustained through week 52 without evidence of tachyphylaxis (tolerance). Women did not need dose escalation to maintain benefit.

At week 52, women on fezolinetant 45 mg also showed statistically significant improvement in sleep disturbance compared with placebo, measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance score. This matters because disrupted sleep is one of the most reported quality-of-life complaints among perimenopausal and postmenopausal women.

What Happens When You Stop Fezolinetant?

SKYLIGHT-1 did not include a formal withdrawal phase, so the rebound kinetics after stopping are not fully characterized. Clinically, VMS are expected to return when the drug is discontinued, because fezolinetant does not alter the underlying estrogen-deficiency state. It suppresses the NK3R-mediated trigger. Think of it less as a cure and more as a long-acting suppressor.

Who Responds Best to Fezolinetant

Based on the SKYLIGHT-1 population and FDA label data, the women most likely to achieve durable response include those with:

• Frequent baseline VMS (seven or more per day), the population in which the greatest absolute reduction was seen
• No current hepatic impairment (fezolinetant is contraindicated in women with moderate or severe liver disease)
• No concomitant CYP1A2 inhibitors such as fluvoxamine, which can raise fezolinetant plasma concentrations significantly

Women in late perimenopause who still have irregular cycles are less well-studied. Most SKYLIGHT participants were at least 12 months postmenopause. If you are still cycling, even irregularly, discuss this with your clinician, because your fluctuating estrogen levels may modulate response unpredictably.

Liver Monitoring Requirement

The FDA label requires liver function testing at baseline and at 3, 6, and 9 months. Fezolinetant caused dose-dependent aminotransferase elevations in trials at the 90 mg dose (not the approved dose), and rare hepatocellular injury has been reported post-marketing. The 45 mg dose carries a lower signal, but monitoring is still mandatory. This monitoring schedule is a real-world durability factor: women who miss labs may have their prescription interrupted.

Intrarosa (Prasterone Vaginal): How Long Does It Keep Working?

Prasterone's durability story is different. The key trial measured outcomes at 12 weeks, but the biology of vaginal tissue restoration suggests that ongoing use produces ongoing benefit.

The Key GSM RCT

The key prasterone RCT (Menopause, 2016) randomized 422 postmenopausal women with self-identified moderate or severe dyspareunia to prasterone 6.5 mg vaginal insert or placebo nightly. At 12 weeks, prasterone produced statistically significant improvements across all four co-primary endpoints:

• Reduction in percentage of parabasal cells (a marker of vaginal atrophy)
• Increase in percentage of superficial cells
• Reduction in vaginal pH from a mean of 6.1 to approximately 5.0
• Reduction in dyspareunia severity scores

The dyspareunia severity score in the prasterone group dropped by 1.42 points on a 0-3 scale versus 0.99 in the placebo group, a statistically significant difference. Vaginal pH and cytology continued to improve through the full 12-week observation period, with no plateau suggesting that durability beyond 12 weeks is biologically plausible.

Beyond 12 Weeks: What the Evidence Shows

No randomized controlled trial has followed prasterone users beyond 12 weeks with a placebo comparator. Open-label extension data and real-world clinical experience suggest that the vaginal tissue improvements are maintained with continued nightly use. The Menopause Society (NAMS) 2023 position statement on GSM notes that vaginal estrogen and locally active vaginal therapies generally require ongoing use to maintain tissue integrity, and this principle applies to prasterone as well.

Stopping Intrarosa typically reverses the vaginal tissue improvements within weeks to months, because the estrogen deprivation that caused atrophy resumes once the local DHEA source is removed.

Systemic Hormone Exposure Over Time

This is a clinically important durability consideration unique to prasterone. When vaginal cells metabolize DHEA, they produce estradiol and testosterone locally. Systemic absorption is low but measurable. In the key trial, serum estradiol remained within the normal postmenopausal range (generally below 10 pg/mL) throughout 12 weeks of nightly use, and testosterone rose modestly but stayed within normal postmenopausal bounds.

For most postmenopausal women, this systemic exposure profile is considered acceptable. But if you have a history of hormone-sensitive breast cancer, or are currently on an aromatase inhibitor, this systemic DHEA conversion warrants a specific oncology-informed discussion before starting prasterone. Current guidelines do not prohibit prasterone in breast cancer survivors, but evidence is still limited, and individual risk-benefit framing is required.

Pregnancy, Lactation, and Contraception: What You Must Know

Both Veozah and Intrarosa are indicated for postmenopausal women. Neither should be used during pregnancy or while breastfeeding.

Fezolinetant in Pregnancy and Lactation

Fezolinetant has no adequate human data in pregnancy. Animal reproductive studies showed adverse fetal effects at exposures above the clinical dose. The FDA label classifies fezolinetant as contraindicated in pregnancy. It is not known whether fezolinetant is excreted in human breast milk. Because this drug is not indicated during reproductive years, contraception requirements are not formally stated in the label. However, any woman in late perimenopause who still has any chance of ovulation should confirm she is not pregnant before starting, and should use reliable contraception if pregnancy is possible.

Prasterone in Pregnancy and Lactation

Prasterone vaginal is contraindicated in pregnancy. DHEA is a steroid hormone precursor, and exogenous prasterone during pregnancy is not studied in humans and carries theoretical fetal androgenization risk. It should not be used during breastfeeding. Women in late perimenopause who may still ovulate occasionally should confirm pregnancy status before starting.

The Perimenopause Nuance

Women in perimenopause often present with both VMS and early GSM. They may still have some ovarian function. Neither of these drugs is designed for perimenopausal women who are still trying to conceive. If you are in perimenopause and have any fertility intent, discuss this with your clinician before starting either agent.

Who Each Drug Is Right For (and Not Right For), by Life Stage

Fezolinetant Is Most Appropriate For Women Who:

• Are postmenopausal (or confirmed anovulatory perimenopause) with frequent moderate-to-severe hot flashes or night sweats
• Want a non-hormonal option because of breast cancer history, personal preference, or contraindication to estrogen
• Have normal liver function and can comply with the required monitoring schedule
• Are not taking strong CYP1A2 inhibitors

Fezolinetant is not appropriate for women with moderate or severe hepatic impairment, women currently pregnant or trying to conceive, or women whose primary complaint is vaginal dryness or painful intercourse with no significant VMS.

Prasterone Is Most Appropriate For Women Who:

• Are postmenopausal with moderate-to-severe dyspareunia, vaginal dryness, or vulvovaginal irritation from GSM
• Want local therapy with minimal systemic hormone exposure
• Have not responded adequately to lubricants or moisturizers alone
• Are comfortable with nightly vaginal self-administration

Prasterone is not appropriate for women who want VMS relief, women with undiagnosed abnormal vaginal bleeding (which requires evaluation before starting any vaginal estrogen or DHEA), or women who are pregnant. Its use in women with active hormone-receptor-positive breast cancer remains an area of active discussion and should involve the treating oncologist.

The Overlap Group: Women With Both VMS and GSM

Postmenopausal women frequently have both. The 2023 Menopause Society position statement on VMS and the separate GSM position statement each acknowledge that women with multiple menopause symptom clusters may need combination therapy. Fezolinetant addresses VMS; prasterone addresses GSM. Using both concurrently is a legitimate clinical strategy when both symptom sets are moderate to severe and systemic hormone therapy is not desired or appropriate.

Should You Switch from Veozah to Intrarosa (or the Reverse)?

Switching makes sense only when you are treating the same symptom and one drug is underperforming. Because Veozah and Intrarosa treat different symptoms, "switching" is usually the wrong frame. The right questions are:

1. Is your hot-flash burden adequately controlled? If no, assess Veozah effectiveness or consider adding or replacing with another VMS therapy.
2. Is your vaginal symptom burden adequately controlled? If no, assess whether Intrarosa or another local therapy is appropriate.

When Switching From Veozah to Intrarosa Might Actually Make Sense

If your primary complaint was originally vaginal dryness and painful intercourse, and you or your clinician initially tried Veozah for concurrent VMS that have since resolved, transitioning away from Veozah to a prasterone-only regimen is reasonable. This simplifies the medication burden and eliminates the liver-monitoring requirement.

When Switching From Intrarosa to Veozah Might Actually Make Sense

If GSM was the original presenting complaint but VMS have escalated and become the dominant quality-of-life problem, and you want to consolidate to a single non-hormonal agent, switching to Veozah (while accepting that vaginal symptoms may worsen) could be appropriate. This is less common because Veozah does not address vaginal tissue.

The Durability Comparison in Plain Terms

| Outcome | Fezolinetant (Veozah) | Prasterone (Intrarosa) | |---|---|---| | Primary symptom | VMS (hot flashes, night sweats) | Dyspareunia / GSM | | Longest RCT follow-up | 52 weeks (SKYLIGHT-1) | 12 weeks (key RCT) | | Durability signal | Sustained at 52 weeks, no tachyphylaxis | Ongoing tissue improvement at 12 weeks; observational data support long-term use | | Effect on stopping | VMS return | Vaginal atrophy resumes | | Head-to-head data | None exist | None exist | | Systemic hormones | None | Low-level estradiol and testosterone from local DHEA conversion |

Monitoring, Adherence, and Real-World Durability Factors

Durability in the real world is not just about pharmacology. It is about whether a woman keeps taking the drug.

Fezolinetant's mandatory liver function monitoring at 3, 6, and 9 months creates four clinic touchpoints in the first year. For women without easy healthcare access, this is a barrier. An FDA safety communication issued in 2024 confirmed rare but serious drug-induced liver injury, reinforcing that monitoring is not optional.

Intrarosa requires nightly vaginal insertion. Adherence data from clinical trials showed high completion rates, but real-world adherence to nightly vaginal medications is variable. Women who miss doses frequently may see reduced tissue-restoration benefit over time. The Menopause Society recommends that women using local vaginal DHEA use it consistently and nightly as labeled.

One adherence advantage of prasterone over vaginal estrogen formulations: some women perceive DHEA as more "natural" or less hormonally significant, which may improve long-term continuation. This perception is not fully accurate given the local hormone conversion, but it is a documented patient experience in clinical practice.

Sex-Specific Pharmacokinetics and Hormonal Context

Fezolinetant's pharmacokinetics have been studied specifically in postmenopausal women. Its half-life is approximately 10 hours, supporting once-daily dosing. CYP1A2 is the primary metabolic enzyme. Women who smoke are CYP1A2 inducers, which may modestly reduce fezolinetant exposure. Women on fluvoxamine (sometimes used for menopause-related mood symptoms or hot flashes off-label) should not combine it with fezolinetant because of inhibition-driven drug accumulation.

Prasterone's intracrinology is inherently sex-specific. DHEA in vaginal epithelial cells undergoes conversion to estradiol and testosterone by enzymes expressed locally. This local conversion is the intended mechanism. In postmenopausal women, the baseline serum DHEA level declines sharply with age and adrenal aging, so exogenous vaginal DHEA is replacing a substrate that the body no longer produces in adequate quantities. This mechanism does not apply in premenopausal women, which is partly why the drug is indicated only in postmenopause.

The NAMS 2022 hormone therapy position statement acknowledges that the benefit-risk profile of any menopause therapy is highly individualized and life-stage-dependent. A 52-year-old woman in early postmenopause with frequent severe hot flashes and early GSM has a different clinical calculus than a 68-year-old woman whose VMS resolved years ago but who continues to have progressive vaginal atrophy.

PCOS, Endometriosis, and Other Female-Relevant Conditions

Neither fezolinetant nor prasterone is studied in women with active PCOS. PCOS typically presents in reproductive-age women, and both drugs are indicated in postmenopause. However, women with a history of PCOS who reach menopause may have a different baseline DHEA or androgen profile that could theoretically affect prasterone's systemic conversion, though no data currently quantify this. Women with a history of endometriosis who are postmenopausal and considering local estrogen-containing therapies (including prasterone, which generates local estradiol) should discuss theoretical endometriosis recurrence risk with their clinician, even though the absolute risk with low-dose local therapy appears very low.

Women with a history of uterine fibroids should note that Intrarosa generates local estradiol. For postmenopausal women, fibroids typically regress after menopause due to estrogen withdrawal. Low-dose local vaginal estrogen or DHEA is unlikely to stimulate fibroid regrowth significantly, but this has not been formally studied in fibroid-specific cohorts.